Johnson & Johnson stock gains as UBS lifts price target to 320 dollars

Johnson & Johnson stock has climbed to record territory after UBS raised its price target to 320 dollars, highlighting stronger growth prospects in the pharma business while valuation metrics signal a demanding starting point for new investors.

Johnson & Johnson stock (ISIN US4781601046) has extended its rally in early September 2026, trading near a record level after a fresh analyst report highlighted faster growth in its pharmaceuticals pipeline and lifted a key Wall Street price target to 320 dollars as of September 2, 2026, according to an analysis shared via GuruFocus.

UBS price target increase drives sentiment

According to an assessment of the latest research reported by GuruFocus on September 2, 2026, UBS raised its price target for Johnson & Johnson from 280 dollars to 320 dollars while reiterating a Buy rating. The move represents an increase of about 14.3% in the target level, signaling greater confidence in the companys medium term earnings power.

A separate market overview citing the same UBS call reported that Johnson & Johnson shares closed around 274.40 to 274.40 dollars on September 2, 2026, up about 1.2% on the day and marking a record close above 275 dollars in intraday trade, with the stock contributing significantly to gains in the Dow Jones Industrial Average. The same report highlighted that UBS sees more upside in the rally despite a richer valuation backdrop.

Strong recent quarter and upgraded 2026 guidance

In its most recent reported quarter, the company delivered a solid set of numbers that underpin the more optimistic stance. As summarized in the GuruFocus-based article on September 2, 2026, Johnson & Johnsons second quarter 2026 results showed sales rising 6.6% year on year to 25.3 billion dollars, a clear acceleration compared with the prior year period. Management at the same time raised the midpoint of its full year 2026 sales forecast to 101.1 billion dollars and lifted adjusted earnings guidance to 11.68 dollars per share, tightening the focus on profitable growth.

The combination of mid single digit revenue growth and upgraded earnings guidance suggests that the company is aiming for operating leverage in the second half of 2026. For investors, a key quantitative takeaway is that the new sales midpoint of 101.1 billion dollars implies an increase of several billion dollars compared with the prior forecast range, while the 11.68 dollars adjusted earnings target sets a higher bar for execution than earlier in the year.

Valuation stretched despite positive analyst tone

The supportive analyst tone is balanced by more cautious valuation metrics. According to a GuruFocus valuation overview dated September 2, 2026, Johnson & Johnsons so called GF Value is calculated at 192.90 dollars per share. With the shares recently trading around 277.94 dollars in that snapshot, the stock stood about 44.1% above this intrinsic value estimate, leading the service to categorize it as significantly overvalued at the current price level.

This valuation gap is central to the risk reward discussion. While UBSs new 320 dollar price target implies around 16.6% upside from a reference price of 274.395 dollars, the 44.1% premium to the GF Value suggests that missteps in late stage clinical trials or slower than expected launches could trigger a sharper pullback. For long term shareholders, the numbers highlight that future share price gains will likely depend more on earnings delivery than on further multiple expansion.

Representative product focus: pharmaceutical portfolio

A large part of the growth case referenced in the UBS analysis relates to Johnson & Johnsons pharmaceutical division, which includes blockbuster therapies in immunology and oncology as well as a pipeline of late stage candidates. While the detailed product breakdown is not part of the latest headlines, the raised 2026 revenue midpoint of 101.1 billion dollars and the 6.6% second quarter sales growth suggest that key drugs continue to gain share in their respective markets and that new launches are contributing meaningfully to the top line.

Johnson & Johnson stock near record levels

On the market side, recent trading data compiled in early September 2026 show Johnson & Johnson stock hovering in the mid 270 dollar range after a series of gains that pushed the shares to fresh record highs around the start of the month. As of the close on September 2, 2026, reference prices around 274 to 276 dollars positioned the stock well above the GF Value estimate of 192.90 dollars yet still below the new 320 dollar analyst target, underlining the tension between optimism on the business and caution on valuation.

Johnson & Johnson stock facts

• Company: Johnson & Johnson
• ISIN: US4781601046
• Ticker: JNJ
• Trading venue: NYSE
• Sector / Industry: Health care / Pharmaceuticals and medical technology